Eurofins Discovery, the leading provider of services and products to the drug discovery industry, today announced a new project with Boehringer Ingelheim’s open innovation portal, opnMe.com . As part of this project, Eurofins Discovery has worked together with Boehringer Ingelheim to profile the entire opnMe portfolio of smal
| ST. CHARLES, Mo., Sept. 21, 2020 /PRNewswire/ -- Eurofins Discovery, the leading provider of services and products to the drug discovery industry, today announced a new project with Boehringer Ingelheim’s open innovation portal, opnMe.com. As part of this project, Eurofins Discovery has worked together with Boehringer Ingelheim to profile the entire opnMe portfolio of small molecules for the assessment of their selectivity by using its gold standard SafetyScreen44 in vitro pharmacology panel, which enables early identification of significant off-target interactions related to in vivo adverse effects, with the goal to further increase value to scientists which work with the opnMe molecules.
Boehringer Ingelheim is sharing well-characterized preclinical tool compound molecules with scientists around the world to enable more scientific opportunities and achieve the ultimate aim of bringing more medical breakthroughs to patients in need. The chemical structure and the data package for these compounds are disclosed on the portal without any conditions. All molecules are provided free of charge on opnMe.com. These molecules are derived from Boehringer Ingelheim’s discovery research pipeline, or were developed in collaboration with external partners of Boehringer Ingelheim. With this “molecules to order” open innovation program, Boehringer Ingelheim aims to help scientists validate their scientific hypotheses and independently publish their data to advance science more quickly. Boehringer Ingelheim puts high emphasis on the quality of its opnMe molecules. Many are provided with a negative control that can be used to validate research experiments. In addition, a good understanding of their selectivity profile is mandatory for the interpretation of any scientific results. For this reason, Boehringer Ingelheim is now applying Eurofins Discovery’s in vitro pharmacology SafetyScreen44 panel to its entire opnMe portfolio and has made available the results for the current molecules via opnMe.com. This further increases the value of this unique set of molecules which are provided free with the scientific community. With the enhanced data achieved from the project, researchers can obtain high quality molecules for their own experiments, which are now supplemented with reliable and valuable profiling data. Learn more about Eurofins Discovery’s In Vitro Pharmacology services at eurofinsdiscoveryservices.com/safety Access Boehringer Ingelheim’s open innovation portal and their molecule profiles at: https://opnMe.com About Eurofins – the global leader in bio-analysis Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 48,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group’s objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff. Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods. As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world. Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP). About opnMe opnMe.com, the new open innovation portal of Boehringer Ingelheim, aims to accelerate research initiatives to enable new insights of disease biology in areas of high unmet medical need by sharing well-characterized molecules and offer collaborations for science. In the spirit of collaboration, the molecules are provided to the scientific community to help unlock and fulfill their full potential. These molecules are either freely available as “Molecules to Order” or applied via scientific research submissions as “Molecules for Collaboration”. As part of a third pillar, the “opn2EXPERTS” program, Boehringer Ingelheim also enlist scientific advice on key biologic issues to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs.
SOURCE Eurofins Discovery | ||
Company Codes: Bloomberg:ERF.FP, ISIN:FR0000038259 |
View original content to download multimedia:
